PDL BioPharma, Inc. Common Equity (Total)

Common Equity (Total) of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Common Equity (Total) growth rates and interactive chart.


Highlights and Quick Summary

  • Common Equity (Total) for the quarter ending June 29, 2020 was $420 Million (a -24.07% decrease compared to previous quarter)
  • Year-over-year quarterly Common Equity (Total) decreased by -34.11%
  • Annual Common Equity (Total) for 2019 was $593 Million (a -18.7% decrease from previous year)
  • Annual Common Equity (Total) for 2018 was $730 Million (a -13.73% decrease from previous year)
  • Annual Common Equity (Total) for 2017 was $846 Million (a 11.98% increase from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Common Equity (Total) of PDL BioPharma, Inc.

Most recent Common Equity (Total)of PDLI including historical data for past 10 years.

Interactive Chart of Common Equity (Total) of PDL BioPharma, Inc.

PDL BioPharma, Inc. Common Equity (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $420.0 $553.12
2019 $593.28 $637.43 $665.42 $693.78 $593.28
2018 $729.78 $739.39 $712.63 $843.11 $729.78
2017 $845.89 $822.98 $818.8 $762.94 $845.89
2016 $755.42 $753.86 $738.65 $742.53 $755.42
2015 $695.95 $595.96 $527.21 $451.94 $695.95
2014 $460.44 $402.01 $296.66 $202.21 $460.44
2013 $113.49 $52.89 $-1.26 $-93.67 $113.49
2012 $-68.12 $-115.48 $-161.11 $-243.78 $-68.12
2011 $-204.27 $-243.24 $-293.51 $-371.2 $-204.27
2010 $-324.18 $-304.54 $-434.86 $-324.18

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.